Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavyret for HCV prevention in kidney transplant
NCT03623568Phase 4Withdrawn
- Start
- Feb 2019
- Primary completion
- Dec 2020
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of glecaprevir in hepatitis C (HCV). Primary endpoint: Undetectable Hepatitis C Virus RNA. Planned start Feb 2019; status: withdrawn.
02
Drugs
glecaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03623568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03623568.